Showing results (181-190 of 219) with videos related to
Sort By:
Pageof 22
Lung Cancer (Amsterdam, Netherlands)|October 9, 2024
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancerDavid Planchard, Jürgen Wolf, Benjamin Solomon, et al.Lung Cancer (Amsterdam, Netherlands)|December 20, 2024
An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancerIlias Houda, Idris Bahce, Chris Dickhoff, et al.Clinical Pharmacology and Therapeutics|May 27, 2025
Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal ImpairmentNikki de Rouw, Leila-Sophie Otten, Mart P Kicken, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2024
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung CancerJordi Remon, Benjamin Besse, Santiago Ponce Aix, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2021
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE StudyFiona Blackhall, Kevin Jao, Laurent Greillier, et al.Cancer Cell|July 18, 2006
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancerBin-Bing S Zhou, Michael Peyton, Biao He, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 1, 2024
Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLCNiels Heersche, Daan A C Lanser, M Benthe Muntinghe-Wagenaar, et al.BMC Cancer|June 17, 2020
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trialRelinde I Y Lieverse, Evert J Van Limbergen, Cary J G Oberije, et al.Journal for Immunotherapy of Cancer|July 24, 2026
Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trialMaria Gonzalez-Cao, Marta Sisteré-Oró, Teresa Moran, et al.Lung Cancer (Amsterdam, Netherlands)|September 30, 2015
Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancerWouter W Mellema, Lucie Masen-Poos, Egbert F Smit, et al.Pageof 22